Breaking News Instant updates and real-time market news.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

, NVS

Novartis

$80.20

-0.86 (-1.06%)

08:26
04/09/18
04/09
08:26
04/09/18
08:26

Bernstein not too surprised with AveXis sale

Bernstein analyst Vincent Chen notes that Novartis (NVS) and AveXis (AVXS) announced an agreement for the former to purchase AveXis for $218 per share, a total of $8.7B. The analyst says he has long suspected he would see acquisitions in gene therapy and that AveXis could be a prime candidate, so he is not too surprised to see it go. However, the analyst acknowledges that he had not pegged Novartis as the top contender. Noting that the announcement should be a positive for others in the space, Chen reiterates an Outperform rating and $144 price target on AveXis shares.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

NVS

Novartis

$80.20

-0.86 (-1.06%)

  • 23

    Apr

  • 17

    May

AVXS AveXis
$115.91

-3.69 (-3.09%)

04/09/18
MZHO
04/09/18
DOWNGRADE
MZHO
Neutral
AveXis downgraded to Neutral from Buy at Mizuho
Mizuho downgraded AveXis (AVXS) to Neutral following the acquisition by Novartis (NVS) for $218 per share in cash.
04/09/18
FBCO
04/09/18
NO CHANGE
Target $170
FBCO
Outperform
AveXis price target raised to $170 from $139 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $170 from $139 to reflect his growing confidence in AVXS-101's ability to treat the broader SMA incidence population, which drives an incremental $200M in annual revenue. The analyst reiterates an Outperform rating on the stock.
02/28/18
FBCO
02/28/18
NO CHANGE
Target $139
FBCO
Outperform
AveXis price target raised to $139 from $134 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for AveXis to $139 from $134 following a "strong" Q4 and as he believes pipeline poised to contribute. The analyst reiterates an Outperform rating on the shares.
02/28/18
WELS
02/28/18
NO CHANGE
Target $171
WELS
Outperform
AveXis price target raised to $171 from $134 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for AveXis to $171 from $134 following review of Q4 progress and on the outlook for its SMA gene therapy and broader pipeline 2018. Overall, the analyst continues to expect approval of AVXS101 gene therapy for type 1 SMA by YE18, and with progress in broader development for type 2 SMA and pre-symptomatic patients with type 1, 2 and 3 SMA, he sees a potential recurring patient population of 5000 patients and $10B in market opportunity, and significant upside potential. Birchenough reiterates an Outperform rating on the shares.
NVS Novartis
$80.20

-0.86 (-1.06%)

03/21/18
WELS
03/21/18
NO CHANGE
WELS
Outperform
Amphastar court win a 'major' positive, says Wells Fargo
Wells Fargo analyst David Maris called the news of Massachusetts' District Court entering a final judgement in favor of Amphastar (AMPH) in the patent lawsuit regarding Lovenox brought by Momenta (MNTA) and Novartis' (NVS) Sandoz division a "major positive" that again demonstrates Amphastar's ability to face down larger, better-funded companies and get difficult products to market. He maintains an Outperform rating on Amphastar shares.
03/02/18
OPCO
03/02/18
INITIATION
Target $16
OPCO
Outperform
Conatus initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Conatus (CNAT) with an Outperform rating and $16 price target based on his view that significant value for shareholders, physicians and patients can be unlocked by the company's "unique" approach to liver disease. In a research note to investors, Olson said he sees emricasan as well positioned to potentially demonstrate efficacy in a broad range of liver diseases, including NASH, adding that the program is viewed as "partially de-risked" through its partnership with Novartis (NVS).
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".

TODAY'S FREE FLY STORIES

PEP

PepsiCo

$116.81

0.14 (0.12%)

16:35
11/15/18
11/15
16:35
11/15/18
16:35
Hot Stocks
PepsiCo maintains 92.75c per share dividend »

This dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Feb

16:34
11/15/18
11/15
16:34
11/15/18
16:34
General news
Money Supply M2 Weekly Change data reported »

Week of 11/5 Money Supply…

16:34
11/15/18
11/15
16:34
11/15/18
16:34
General news
Fed Balance Sheet Level data reported »

Week of 11/14 Fed Balance…

AMH

American Homes 4 Rent

$19.87

-0.42 (-2.07%)

16:34
11/15/18
11/15
16:34
11/15/18
16:34
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNVR

Univar

$23.10

0.07 (0.30%)

16:34
11/15/18
11/15
16:34
11/15/18
16:34
Hot Stocks
Univar, Buckman reach distribution pact for U.S., Canada »

Univar announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$53.28

0.67 (1.27%)

16:33
11/15/18
11/15
16:33
11/15/18
16:33
Hot Stocks
Bristol-Myers receives positive CHMP opinion recommending Opdivo plus Yervoy »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

KAMN

Kaman

$57.82

0.41 (0.71%)

16:32
11/15/18
11/15
16:32
11/15/18
16:32
Hot Stocks
Kaman awarded $52M addition to Option 14 of its USAF JPF order »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$99.62

-1.96 (-1.93%)

, CSCO

Cisco

$46.77

2.42 (5.46%)

16:32
11/15/18
11/15
16:32
11/15/18
16:32
OnTheFly
Fly Intel: Wall Street's top stories for Thursday »

Stocks opened in negative…

WMT

Walmart

$99.62

-1.96 (-1.93%)

CSCO

Cisco

$46.77

2.42 (5.46%)

FB

Facebook

$143.86

-0.39 (-0.27%)

QURE

uniQure

$31.00

8.21 (36.02%)

ORCL

Oracle

$50.64

1.8 (3.69%)

BRK.A

Berkshire Hathaway

$325,810.00

1410 (0.43%)

PCG

PG&E

$17.77

-7.89 (-30.75%)

DDS

Dillard's

$62.62

-11.01 (-14.95%)

NTAP

NetApp

$68.84

-9.21 (-11.80%)

BRK.B

Berkshire Hathaway

$217.49

1.465 (0.68%)

RYB

RYB Education

$7.82

-8.99 (-53.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 10

    Jan

INTC

Intel

$48.12

1.03 (2.19%)

16:31
11/15/18
11/15
16:31
11/15/18
16:31
Hot Stocks
Intel board approves $15B increase in authorized stock repurchase program »

Intel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

TGT

Target

$80.76

-2.35 (-2.83%)

16:31
11/15/18
11/15
16:31
11/15/18
16:31
Initiation
Target initiated  »

Target initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

NVDA

Nvidia

$202.65

5.43 (2.75%)

16:30
11/15/18
11/15
16:30
11/15/18
16:30
Hot Stocks
Nvidia board authorizes additional $7B under share buyback program »

In November 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

LTRX

Lantronix

$3.51

0.03 (0.86%)

16:30
11/15/18
11/15
16:30
11/15/18
16:30
Syndicate
Breaking Syndicate news story on Lantronix »

Lantronix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

16:30
11/15/18
11/15
16:30
11/15/18
16:30
Hot Stocks
Nvidia raises quarterly dividend 7% to 16c per share »

Nvidia announced a 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

16:30
11/15/18
11/15
16:30
11/15/18
16:30
Options
Preliminary option volume of 24.1M today »

Preliminary option volume…

GOGL

Golden Ocean

$6.68

0.19 (2.93%)

, SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

16:29
11/15/18
11/15
16:29
11/15/18
16:29
Initiation
Golden Ocean, Scorpio Bulkers initiated  »

Golden Ocean, Scorpio…

GOGL

Golden Ocean

$6.68

0.19 (2.93%)

SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

16:28
11/15/18
11/15
16:28
11/15/18
16:28
Earnings
Nvidia sees Q4 revenue $2.7B, +/- 2%, consensus $3.4B »

GAAP and non-GAAP gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

16:27
11/15/18
11/15
16:27
11/15/18
16:27
Earnings
Nvidia reports Q3 adjusted EPS $1.84, consensus $1.71 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

NCS

NCI Building

$12.25

-0.095 (-0.77%)

16:26
11/15/18
11/15
16:26
11/15/18
16:26
Hot Stocks
NCI Building shareholders vote in favor of merger with Ply Gem »

NCI Building's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

MTEM

Molecular Templates

$4.53

0.12 (2.72%)

16:26
11/15/18
11/15
16:26
11/15/18
16:26
Initiation
Molecular Templates initiated  »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$44.45

-0.13 (-0.29%)

16:25
11/15/18
11/15
16:25
11/15/18
16:25
Hot Stocks
Western Gas Partners announces management changes, promotions »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

BGCP

BGC Partners

$10.66

0.24 (2.30%)

16:25
11/15/18
11/15
16:25
11/15/18
16:25
Hot Stocks
Breaking Hot Stocks news story on BGC Partners »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$55.49

1.09 (2.00%)

16:25
11/15/18
11/15
16:25
11/15/18
16:25
Hot Stocks
Anadarko raises dividend 20% to 30c per share »

On Nov. 15, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:25
11/15/18
11/15
16:25
11/15/18
16:25
Conference/Events
UBS MLPs & Natural Gas Analyst to hold a group dinner »

MLPs & Natural Gas…

GNBC

Green Bancorp

$18.71

0.53 (2.92%)

, VBTX

Veritex

$23.60

0.66 (2.88%)

16:25
11/15/18
11/15
16:25
11/15/18
16:25
Conference/Events
Green Bancorp to host special shareholder meeting »

Special Shareholder…

GNBC

Green Bancorp

$18.71

0.53 (2.92%)

VBTX

Veritex

$23.60

0.66 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

MATW

Matthews

$40.30

-1 (-2.42%)

16:24
11/15/18
11/15
16:24
11/15/18
16:24
Hot Stocks
Matthews sees FY19 adjusted EBITDA growth in mid-to-high single digits »

Matthews' president…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.